OpGen（6500）株式概要プレシジョン・メディシン企業であるオプジェン社は、生命を脅かす感染症に対する分子微生物学的ソリューションを米国内外で開発・商品化している。 詳細6500 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析株式の流動性は非常に低い 過去1年間で株主の希薄化は大幅に進んだ 過去5年間で収益は年間6.5%減少しました。 キャッシュランウェイが1年未満である +2 さらなるリスクすべてのリスクチェックを見る6500 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€1.572.0k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-41m4m2016201920222025202620282031Revenue US$774.6kEarnings US$140.8kAdvancedSet Fair ValueView all narrativesOpGen, Inc. 競合他社Genetic AnalysisSymbol: DB:8V8Market cap: €42.7mDarwinSymbol: MUN:7V0Market cap: €68.4mDextech MedicalSymbol: DB:LQ0Market cap: €184.9mHeidelberg PharmaSymbol: XTRA:HPHAMarket cap: €130.5m価格と性能株価の高値、安値、推移の概要OpGen過去の株価現在の株価US$1.5752週高値US$3.5552週安値US$1.42ベータ-0.491ヶ月の変化0%3ヶ月変化0%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-55.18%最新ニュースお知らせ • May 16CapForce Inc. announced delayed 10-Q filingOn 05/15/2026, CapForce Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01CapForce Inc. announced delayed annual 10-K filingOn 03/31/2026, CapForce Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 28OpGen, Inc., Annual General Meeting, Feb 23, 2026OpGen, Inc., Annual General Meeting, Feb 23, 2026.お知らせ • Dec 06+ 1 more updateCapForce International Holdings Ltd., Subsidiary of OpGen, Inc. Approves Promotion of Christian-Laurent Bonte as Chief Executive Officer, Effective December 1, 2025OpGen, Inc. announced that on December 1, 2025, Mr. Christian-Laurent Bonte entered into a promotion letter with CapForce International Holdings Ltd. (CapForce), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company, pursuant to which he will serve as Chief Executive Officer of CapForce (the “Promotion Letter”). Pursuant to the Promotion Letter, Mr. Bonte’s employment may be terminated by CapForce at any time by one (1) month written notice by CapForce. Mr. Bonte, age 49, was a member of the Board until July 17, 2025, when he resigned from the Board and was appointed, pursuant to an offer letter dated June 25, 2025 (the “Offer Letter”), the Head of the Digital Investment Banking Arm of CapForce International Holdings Ltd. (“CapForce”), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company. Mr. Bonte will continue to leverage his rich investment banking experience in Hong Kong and Singapore with broad in-depth Hong Kong and U.S. capital market exposure. Mr. Bonte’s experience includes serving as the Executive Director at Meyzer Capital Management Pte Ltd, a management consulting and alternative investments platform, since March 2024, as the Founder and the Managing Director of Far Cap Pte Ltd, a corporate finance and technology investment firm, from December 2021 to March 2024, and as the Managing Director of ARC Capital Ltd, an investment bank with a presence in Asia and the United States, from August 2017 to December 2021. CapForce International Holdings Ltd. announced to offer Mr. Christian Bonte, the full time position of Head of Investment Banking Arm, reporting to CapForce CEO and working alongside CapForce COO. The position is offered on the following terms.お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • May 16CapForce Inc. announced delayed 10-Q filingOn 05/15/2026, CapForce Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01CapForce Inc. announced delayed annual 10-K filingOn 03/31/2026, CapForce Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 28OpGen, Inc., Annual General Meeting, Feb 23, 2026OpGen, Inc., Annual General Meeting, Feb 23, 2026.お知らせ • Dec 06+ 1 more updateCapForce International Holdings Ltd., Subsidiary of OpGen, Inc. Approves Promotion of Christian-Laurent Bonte as Chief Executive Officer, Effective December 1, 2025OpGen, Inc. announced that on December 1, 2025, Mr. Christian-Laurent Bonte entered into a promotion letter with CapForce International Holdings Ltd. (CapForce), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company, pursuant to which he will serve as Chief Executive Officer of CapForce (the “Promotion Letter”). Pursuant to the Promotion Letter, Mr. Bonte’s employment may be terminated by CapForce at any time by one (1) month written notice by CapForce. Mr. Bonte, age 49, was a member of the Board until July 17, 2025, when he resigned from the Board and was appointed, pursuant to an offer letter dated June 25, 2025 (the “Offer Letter”), the Head of the Digital Investment Banking Arm of CapForce International Holdings Ltd. (“CapForce”), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company. Mr. Bonte will continue to leverage his rich investment banking experience in Hong Kong and Singapore with broad in-depth Hong Kong and U.S. capital market exposure. Mr. Bonte’s experience includes serving as the Executive Director at Meyzer Capital Management Pte Ltd, a management consulting and alternative investments platform, since March 2024, as the Founder and the Managing Director of Far Cap Pte Ltd, a corporate finance and technology investment firm, from December 2021 to March 2024, and as the Managing Director of ARC Capital Ltd, an investment bank with a presence in Asia and the United States, from August 2017 to December 2021. CapForce International Holdings Ltd. announced to offer Mr. Christian Bonte, the full time position of Head of Investment Banking Arm, reporting to CapForce CEO and working alongside CapForce COO. The position is offered on the following terms.お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17OpGen, Inc. announced delayed 10-Q filingOn 05/16/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01OpGen, Inc. announced delayed annual 10-K filingOn 03/31/2025, OpGen, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Dec 28OpGen Provides Nasdaq Minimum Stockholders’ Equity Requirement Non-Compliance UpdateOn December 19, 2024, despite OpGen, Inc. regaining short-term compliance with the minimum stockholders' equity requirement of the Nasdaq Capital Market (Nasdaq") pursuant to Nasdaq Listing Rule 5550(b)(1) after the deadline for such compliance granted to the Company prior to AEI Capital Ltd. acquiring a controlling interest in the Company, the Nasdaq Listing and Hearing Review Council (the Listing Council") affirmed the decision of the Nasdaq Hearings Panel (the Panel"). As previously disclosed, on August 16, 2024, the Company received written notice of the Panel's determination to effect a trading suspension and delisting of the Company's securities based upon the Company's continued non-compliance with the minimum stockholders' equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the Stockholders' Equity Rule"). While the trading suspension was effective as of August 20, 2024, the Company had appealed the Panel's decision to the Listing Council. Although the Company continues to disagree with the Listing Council's decision, as a result of such decision, unless Nasdaq's Board of Directors determines to review such decision pursuant to Nasdaq Listing Rule 5825, Nasdaq will ultimately file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the Commission") that will remove the Company's securities from listing on Nasdaq. The filing of the Form 25 had been stayed pending the Company's appeal of the Panel's decision to the Listing Council. The Company's shares of common stock will continue trading on the OTC Markets under the symbol OPGN" following the filing of the Form 25 with the Commission. Consistent with the Listing Council's decision, the Listing Council welcomes the Company's application for relisting and the Company plans to apply for relisting with The Nasdaq Stock Market LLC after meeting the relevant Nasdaq listing requirements.お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 23+ 1 more updateOpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on NasdaqAs previously disclosed on June 11, 2024, OpGen, Inc. (the ‘Company’) received a letter from the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) that the Company was no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the ‘Stockholders’ Equity Rule’). The Stockholders’ Equity Rule requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet alternatives of market value of listed securities or net income from continuing operations, which the Company does not currently meet. In response to the letter, the Company submitted its plan to regain compliance with the Stockholders’ Equity Rule to the Nasdaq Hearings Panel (the ‘Panel’) and requested additional time to regain compliance with such rule. On August 16, 2024, following the Panel’s review of the Company’s plan to regain compliance, the Company received a letter (the ‘Notice’) indicating that the Panel had determined to deny the Company’s request for continued listing on Nasdaq. Pursuant to the Notice, based on the preliminary nature of the Company’s plan, the Panel determined that the Company did not provide a definitive plan evidencing its ability to achieve near- and long-term compliance with the Stockholders’ Equity Requirement. Unless the Company requests an appeal of the Panel’s determination by August 31, 2024, Nasdaq will file a Form 25 Notification of Delisting with the SEC, which will remove the Company’s securities from listing on the Nasdaq Capital Market. The Notice also provided that the Company’s securities will be suspended from trading on the Nasdaq Capital Market at the opening of business on August 20, 2024. The Company currently intends to timely appeal this determination by requesting that the Nasdaq Listing and Hearing Review Council review the decision of the Panel. Such appeal will stay the delisting of the Company’s securities with Nasdaq and the filing of the Form 25 pending the Panel’s decision until the resolution of such review. There can be no assurance that the Nasdaq Listing and Hearing Review Council will grant the Company’s request for continued listing on Nasdaq. The Company continues to pursue various steps to regain compliance with the Stockholders’ Equity Rule. Most recently, on August 19, 2024, pursuant to the previously disclosed settlement agreements (the ‘Settlement Agreements’) with each of the European Investment Bank, the Company’s senior creditor (the ‘EIB’), and Curetis GmbH, the Company’s subsidiary in insolvency (‘Curetis’), the Company paid and settled its outstanding indebtedness with the EIB and Curetis. The settlement agreement with the EIB also terminated that certain Guarantee and Indemnity Agreement, dated as of July 9, 2024 (the ‘Guarantee Agreement’), by and between the Company and EIB, pursuant to which the Company had guaranteed all of Curetis’ debt to EIB. The foregoing description of the Settlement Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of such Settlement Agreements, which are filed as Exhibits 10.2 and 10.3, respectively, to this Current Report on Form 8-K and incorporated herein by reference. In addition, as described in Item 1.01 of this Current Report on Form 8-K, the Company entered into the Purchase Agreement on August 22, 2024, pursuant to which the Company may sell the Shares for aggregate gross proceeds of up to $3,000,000. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. As a result of such settlements and the Financing, the Company expects its increased stockholders’ equity will result in the Company regaining compliance with the Stockholders’ Equity Rule. The Company plans to pursue further steps to cause the Company to maintain ongoing compliance with the Stockholders’ Equity Rule. Notwithstanding the foregoing, there can be no assurance that the Company will be successful in its efforts to regain and maintain such compliance.お知らせ • Aug 22OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI IndexOpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Indexお知らせ • Aug 21OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite IndexOpGen, Inc. has been dropped from the Nasdaq Composite Index.お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Reported Earnings • Jul 09First quarter 2024 earnings released: EPS: US$0.21 (vs US$12.53 loss in 1Q 2023)First quarter 2024 results: EPS: US$0.21 (up from US$12.53 loss in 1Q 2023). Revenue: US$168.1k (down 82% from 1Q 2023). Net income: US$272.8k (up US$6.01m from 1Q 2023).お知らせ • Jun 13OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on NasdaqAs previously disclosed, the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) notified OpGen, Inc. (the ‘Company’) on June 5, 2023 that the Company’s common stock had failed to maintain a minimum bid price of $1.00 per share for the 30 consecutive business days preceding the date of such notice as required by Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Rule’). In December 2023, the Company appealed such determination to a Nasdaq Hearings Panel, which in February 2024, granted the Company’s request for an additional period to regain compliance with the Minimum Bid Price Rule. On June 5, 2024, the Nasdaq Hearings Panel notified the Company that it had regained compliance with the Minimum Bid Price Rule. In addition, on June 5, 2024, the Company received a notice from Nasdaq stating that the Company is not in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet the alternatives of market value of listed securities or net income from continuing operations. The notice indicated that such delinquency serves as an additional basis for delisting the Company’s securities from Nasdaq. In accordance with the notice, the Company submitted its response to the Nasdaq Hearings Panel on June 11, 2024 regarding such delinquency and the Company’s plan to cure such delinquency. As with the prior notices received by the Company, the most recent notice from Nasdaq has no immediate effect on the listing of the Company’s securities on The Nasdaq Capital Market. There can be no assurance that the Nasdaq Hearings Panel will grant the Company additional time to cure such deficiency or, if additional time is granted, that the Company will be able to regain compliance with the requirements for continued listing.お知らせ • Jun 05Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024As previously disclosed in a Current Report on Form 8-K filed on May 24, 2024, OpGen, Inc. (the Company") received an additional notice from The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the Form 10-Q") and was therefore not in compliance with Nasdaq Listing Rule 5250(c)(1). Following submission of the Company's plan to cure such delinquency, on May 29, 2024, the Nasdaq Hearings Panel granted the Company's request for continued listing subject to the Company filing its Form 10-Q by July 8, 2024. The Company plans to file its Form 10-Q as soon as practicable; however, no assurance can be given as to the definitive date on which such report will be filed.New Risk • Jun 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$12m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Shares are highly illiquid. Negative equity (-US$12m). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Market cap is less than US$10m (€2.95m market cap, or US$3.21m). Minor Risk Revenue is less than US$5m (US$3.4m revenue).New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Shares are highly illiquid. Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Market cap is less than US$10m (€3.56m market cap, or US$3.86m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Revenue is less than US$5m (US$3.1m revenue).Board Change • May 28No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Member of Clinical Advisory Board Stefan Riedel is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.株主還元6500DE BiotechsDE 市場7D0%-0.2%3.2%1Yn/a-12.1%2.5%株主還元を見る業界別リターン: 6500がGerman Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: 6500 German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is 6500's price volatile compared to industry and market?6500 volatility6500 Average Weekly Movementn/aBiotechs Industry Average Movement8.5%Market Average Movement6.1%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.7%安定した株価: 6500の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の6500のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2001n/aJohn Tanwww.opgen.comプレシジョン・メディシン企業であるオプジェン社は、生命を脅かす感染症に対する分子微生物学的ソリューションを米国内外で開発・商品化している。同社の製品には、Unyveroアプリケーションカートリッジ、Unyveroシステム、Acuitas AMR遺伝子パネル検査製品、SARS CoV-2検査キットなどがある。同社はラボサービス、資金提供によるソフトウェアの手配を含むコラボレーションサービス、ライセンス手配サービスを提供している。オプジェン社は2001年に設立され、メリーランド州ロックビルに本社を置いている。もっと見るOpGen, Inc. 基礎のまとめOpGen の収益と売上を時価総額と比較するとどうか。6500 基礎統計学時価総額€9.16m収益（TTM）-€9.57m売上高(TTM)€1.22m7.5xP/Sレシオ-1.0xPER（株価収益率6500 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6500 損益計算書（TTM）収益US$1.27m売上原価US$1.59m売上総利益-US$323.88kその他の費用US$9.59m収益-US$9.92m直近の収益報告Sep 30, 2024次回決算日該当なし一株当たり利益（EPS）-0.99グロス・マージン-25.59%純利益率-783.50%有利子負債／自己資本比率0%6500 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/02/02 06:33終値2024/11/05 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CapForce Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Benjamin HaynorAlliance Global Partnersnull nullBrookline Capital MarketsNidhi SinghEdison Investment Research2 その他のアナリストを表示
お知らせ • May 16CapForce Inc. announced delayed 10-Q filingOn 05/15/2026, CapForce Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01CapForce Inc. announced delayed annual 10-K filingOn 03/31/2026, CapForce Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 28OpGen, Inc., Annual General Meeting, Feb 23, 2026OpGen, Inc., Annual General Meeting, Feb 23, 2026.
お知らせ • Dec 06+ 1 more updateCapForce International Holdings Ltd., Subsidiary of OpGen, Inc. Approves Promotion of Christian-Laurent Bonte as Chief Executive Officer, Effective December 1, 2025OpGen, Inc. announced that on December 1, 2025, Mr. Christian-Laurent Bonte entered into a promotion letter with CapForce International Holdings Ltd. (CapForce), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company, pursuant to which he will serve as Chief Executive Officer of CapForce (the “Promotion Letter”). Pursuant to the Promotion Letter, Mr. Bonte’s employment may be terminated by CapForce at any time by one (1) month written notice by CapForce. Mr. Bonte, age 49, was a member of the Board until July 17, 2025, when he resigned from the Board and was appointed, pursuant to an offer letter dated June 25, 2025 (the “Offer Letter”), the Head of the Digital Investment Banking Arm of CapForce International Holdings Ltd. (“CapForce”), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company. Mr. Bonte will continue to leverage his rich investment banking experience in Hong Kong and Singapore with broad in-depth Hong Kong and U.S. capital market exposure. Mr. Bonte’s experience includes serving as the Executive Director at Meyzer Capital Management Pte Ltd, a management consulting and alternative investments platform, since March 2024, as the Founder and the Managing Director of Far Cap Pte Ltd, a corporate finance and technology investment firm, from December 2021 to March 2024, and as the Managing Director of ARC Capital Ltd, an investment bank with a presence in Asia and the United States, from August 2017 to December 2021. CapForce International Holdings Ltd. announced to offer Mr. Christian Bonte, the full time position of Head of Investment Banking Arm, reporting to CapForce CEO and working alongside CapForce COO. The position is offered on the following terms.
お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16CapForce Inc. announced delayed 10-Q filingOn 05/15/2026, CapForce Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01CapForce Inc. announced delayed annual 10-K filingOn 03/31/2026, CapForce Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 28OpGen, Inc., Annual General Meeting, Feb 23, 2026OpGen, Inc., Annual General Meeting, Feb 23, 2026.
お知らせ • Dec 06+ 1 more updateCapForce International Holdings Ltd., Subsidiary of OpGen, Inc. Approves Promotion of Christian-Laurent Bonte as Chief Executive Officer, Effective December 1, 2025OpGen, Inc. announced that on December 1, 2025, Mr. Christian-Laurent Bonte entered into a promotion letter with CapForce International Holdings Ltd. (CapForce), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company, pursuant to which he will serve as Chief Executive Officer of CapForce (the “Promotion Letter”). Pursuant to the Promotion Letter, Mr. Bonte’s employment may be terminated by CapForce at any time by one (1) month written notice by CapForce. Mr. Bonte, age 49, was a member of the Board until July 17, 2025, when he resigned from the Board and was appointed, pursuant to an offer letter dated June 25, 2025 (the “Offer Letter”), the Head of the Digital Investment Banking Arm of CapForce International Holdings Ltd. (“CapForce”), a limited liability company incorporated in Malaysia and wholly owned subsidiary of the Company. Mr. Bonte will continue to leverage his rich investment banking experience in Hong Kong and Singapore with broad in-depth Hong Kong and U.S. capital market exposure. Mr. Bonte’s experience includes serving as the Executive Director at Meyzer Capital Management Pte Ltd, a management consulting and alternative investments platform, since March 2024, as the Founder and the Managing Director of Far Cap Pte Ltd, a corporate finance and technology investment firm, from December 2021 to March 2024, and as the Managing Director of ARC Capital Ltd, an investment bank with a presence in Asia and the United States, from August 2017 to December 2021. CapForce International Holdings Ltd. announced to offer Mr. Christian Bonte, the full time position of Head of Investment Banking Arm, reporting to CapForce CEO and working alongside CapForce COO. The position is offered on the following terms.
お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17OpGen, Inc. announced delayed 10-Q filingOn 05/16/2025, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01OpGen, Inc. announced delayed annual 10-K filingOn 03/31/2025, OpGen, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Dec 28OpGen Provides Nasdaq Minimum Stockholders’ Equity Requirement Non-Compliance UpdateOn December 19, 2024, despite OpGen, Inc. regaining short-term compliance with the minimum stockholders' equity requirement of the Nasdaq Capital Market (Nasdaq") pursuant to Nasdaq Listing Rule 5550(b)(1) after the deadline for such compliance granted to the Company prior to AEI Capital Ltd. acquiring a controlling interest in the Company, the Nasdaq Listing and Hearing Review Council (the Listing Council") affirmed the decision of the Nasdaq Hearings Panel (the Panel"). As previously disclosed, on August 16, 2024, the Company received written notice of the Panel's determination to effect a trading suspension and delisting of the Company's securities based upon the Company's continued non-compliance with the minimum stockholders' equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the Stockholders' Equity Rule"). While the trading suspension was effective as of August 20, 2024, the Company had appealed the Panel's decision to the Listing Council. Although the Company continues to disagree with the Listing Council's decision, as a result of such decision, unless Nasdaq's Board of Directors determines to review such decision pursuant to Nasdaq Listing Rule 5825, Nasdaq will ultimately file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the Commission") that will remove the Company's securities from listing on Nasdaq. The filing of the Form 25 had been stayed pending the Company's appeal of the Panel's decision to the Listing Council. The Company's shares of common stock will continue trading on the OTC Markets under the symbol OPGN" following the filing of the Form 25 with the Commission. Consistent with the Listing Council's decision, the Listing Council welcomes the Company's application for relisting and the Company plans to apply for relisting with The Nasdaq Stock Market LLC after meeting the relevant Nasdaq listing requirements.
お知らせ • Nov 15OpGen, Inc. announced delayed 10-Q filingOn 11/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 23+ 1 more updateOpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on NasdaqAs previously disclosed on June 11, 2024, OpGen, Inc. (the ‘Company’) received a letter from the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) that the Company was no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(b)(1) (the ‘Stockholders’ Equity Rule’). The Stockholders’ Equity Rule requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet alternatives of market value of listed securities or net income from continuing operations, which the Company does not currently meet. In response to the letter, the Company submitted its plan to regain compliance with the Stockholders’ Equity Rule to the Nasdaq Hearings Panel (the ‘Panel’) and requested additional time to regain compliance with such rule. On August 16, 2024, following the Panel’s review of the Company’s plan to regain compliance, the Company received a letter (the ‘Notice’) indicating that the Panel had determined to deny the Company’s request for continued listing on Nasdaq. Pursuant to the Notice, based on the preliminary nature of the Company’s plan, the Panel determined that the Company did not provide a definitive plan evidencing its ability to achieve near- and long-term compliance with the Stockholders’ Equity Requirement. Unless the Company requests an appeal of the Panel’s determination by August 31, 2024, Nasdaq will file a Form 25 Notification of Delisting with the SEC, which will remove the Company’s securities from listing on the Nasdaq Capital Market. The Notice also provided that the Company’s securities will be suspended from trading on the Nasdaq Capital Market at the opening of business on August 20, 2024. The Company currently intends to timely appeal this determination by requesting that the Nasdaq Listing and Hearing Review Council review the decision of the Panel. Such appeal will stay the delisting of the Company’s securities with Nasdaq and the filing of the Form 25 pending the Panel’s decision until the resolution of such review. There can be no assurance that the Nasdaq Listing and Hearing Review Council will grant the Company’s request for continued listing on Nasdaq. The Company continues to pursue various steps to regain compliance with the Stockholders’ Equity Rule. Most recently, on August 19, 2024, pursuant to the previously disclosed settlement agreements (the ‘Settlement Agreements’) with each of the European Investment Bank, the Company’s senior creditor (the ‘EIB’), and Curetis GmbH, the Company’s subsidiary in insolvency (‘Curetis’), the Company paid and settled its outstanding indebtedness with the EIB and Curetis. The settlement agreement with the EIB also terminated that certain Guarantee and Indemnity Agreement, dated as of July 9, 2024 (the ‘Guarantee Agreement’), by and between the Company and EIB, pursuant to which the Company had guaranteed all of Curetis’ debt to EIB. The foregoing description of the Settlement Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of such Settlement Agreements, which are filed as Exhibits 10.2 and 10.3, respectively, to this Current Report on Form 8-K and incorporated herein by reference. In addition, as described in Item 1.01 of this Current Report on Form 8-K, the Company entered into the Purchase Agreement on August 22, 2024, pursuant to which the Company may sell the Shares for aggregate gross proceeds of up to $3,000,000. The information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. As a result of such settlements and the Financing, the Company expects its increased stockholders’ equity will result in the Company regaining compliance with the Stockholders’ Equity Rule. The Company plans to pursue further steps to cause the Company to maintain ongoing compliance with the Stockholders’ Equity Rule. Notwithstanding the foregoing, there can be no assurance that the Company will be successful in its efforts to regain and maintain such compliance.
お知らせ • Aug 22OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI IndexOpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index
お知らせ • Aug 21OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite IndexOpGen, Inc. has been dropped from the Nasdaq Composite Index.
お知らせ • Aug 15OpGen, Inc. announced delayed 10-Q filingOn 08/14/2024, OpGen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Reported Earnings • Jul 09First quarter 2024 earnings released: EPS: US$0.21 (vs US$12.53 loss in 1Q 2023)First quarter 2024 results: EPS: US$0.21 (up from US$12.53 loss in 1Q 2023). Revenue: US$168.1k (down 82% from 1Q 2023). Net income: US$272.8k (up US$6.01m from 1Q 2023).
お知らせ • Jun 13OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on NasdaqAs previously disclosed, the listing staff of The Nasdaq Stock Market LLC (‘Nasdaq’) notified OpGen, Inc. (the ‘Company’) on June 5, 2023 that the Company’s common stock had failed to maintain a minimum bid price of $1.00 per share for the 30 consecutive business days preceding the date of such notice as required by Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Rule’). In December 2023, the Company appealed such determination to a Nasdaq Hearings Panel, which in February 2024, granted the Company’s request for an additional period to regain compliance with the Minimum Bid Price Rule. On June 5, 2024, the Nasdaq Hearings Panel notified the Company that it had regained compliance with the Minimum Bid Price Rule. In addition, on June 5, 2024, the Company received a notice from Nasdaq stating that the Company is not in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 or to meet the alternatives of market value of listed securities or net income from continuing operations. The notice indicated that such delinquency serves as an additional basis for delisting the Company’s securities from Nasdaq. In accordance with the notice, the Company submitted its response to the Nasdaq Hearings Panel on June 11, 2024 regarding such delinquency and the Company’s plan to cure such delinquency. As with the prior notices received by the Company, the most recent notice from Nasdaq has no immediate effect on the listing of the Company’s securities on The Nasdaq Capital Market. There can be no assurance that the Nasdaq Hearings Panel will grant the Company additional time to cure such deficiency or, if additional time is granted, that the Company will be able to regain compliance with the requirements for continued listing.
お知らせ • Jun 05Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024As previously disclosed in a Current Report on Form 8-K filed on May 24, 2024, OpGen, Inc. (the Company") received an additional notice from The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company was delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the Form 10-Q") and was therefore not in compliance with Nasdaq Listing Rule 5250(c)(1). Following submission of the Company's plan to cure such delinquency, on May 29, 2024, the Nasdaq Hearings Panel granted the Company's request for continued listing subject to the Company filing its Form 10-Q by July 8, 2024. The Company plans to file its Form 10-Q as soon as practicable; however, no assurance can be given as to the definitive date on which such report will be filed.
New Risk • Jun 04New major risk - Negative shareholders equityThe company has negative equity. Total equity: -US$12m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Shares are highly illiquid. Negative equity (-US$12m). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Market cap is less than US$10m (€2.95m market cap, or US$3.21m). Minor Risk Revenue is less than US$5m (US$3.4m revenue).
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$18m free cash flow). Shares are highly illiquid. Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (106% increase in shares outstanding). Market cap is less than US$10m (€3.56m market cap, or US$3.86m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Revenue is less than US$5m (US$3.1m revenue).
Board Change • May 28No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Member of Clinical Advisory Board Stefan Riedel is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
